Prognostic Impact Of Baseline Immunologic Profile In Aggressive B-cell Non-Hodgkin’s Lymphomas

Main Article Content

Safaa M. Ramadan


Immunologlobulin, IGG, Prognosis, Aggressive B-cell Non-Hodgkin’s Lymphoma, lymphocyte-monocyte ratio


Not requested


Download data is not yet available.

Abstract 694
PDF Downloads 185
HTML Downloads 136


1. Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. Pizzi M, Boi M, Bertoni F, Inghirami G. Leukemia, 2016, p. 30,1805–1815.
2. Lymphoma: immune evasion strategies. Upadhyay R, Hammerich L, Peng P, Brown B, Merad M, Brody JD. Cancers (Basel), 2015, p. 736-62.
3. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, et al. Haematologica, 2012, p. 97:262–269.
4. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, Go H, et al. Oncologist , 2012, p. 17:871– 880 .
5. Absolute lymphocyte count is a prognostic factor for diffuse large B-cell lymphoma. Cox MC, Nofroni I, Laverde G, Ferrari A, Amodeo R, Tatarelli C, Saltarelli F, et al. Br J Haematol, 2008, p. 191:265–268.
6. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef INM, Johnston PB, et al. Leukemia, 2011, p. 25:1502–1509.
7. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, et al. PLoS One, 2012, p. 7:e41658.
8. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, et al. Am J Hematol, 2013, p. 88,1062-1067.
9. Hypogammaglobulinemia in chronic lymphocytic leukemia: a predictor of outcome? Reda G, Cassin R, Levati G, Fattizzo B, Mattiello V, Giannarelli D,et al. Blood, 2017, p. 30:2997.
10. Does hypogammaglobulinemia at diagosis effects survival and infection risk in chronic lymphocytic leukemia (CLL)? Atilla E, Atilla PA, Civriz Bozdag S, Toprak SK, et al. Blood, 2016, p. 128:5577.
11. Natural history of hypogammaglobulinemia in patients with follicular lymphoma and the impact of anti-CD20-based therapy. Fischer T, Ni A, Soumerai JD, Alperovich A, Batlevi CL, et al. Blood, 2017, p. 130:4054.
12. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study. De Angelis F, Tosti ME, Capria S, Russo E, D’Elia GM, et al. Leukemia Research, 2015, p. 1382–1388.
13. Autologous transplantation for Diffuse Large B Cell Lymphoma: pre-transplant hypogammaglobulinemia is a predictor for early toxicities. Bolwell BJ, Kalaycio M, Sobecks R, Andresen S, Rybicki L, et al. Blood, 2004, p. 104:908.
14. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, et al. Blood, 2016, p. 127(20):2375-90.
15. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non- Hodgkin Lymphoma: The Lugano Classification. Cheson BD, Fisher RI, Barrington SF, Cavalli F, et al. J Clin Oncol, 2014, p. 32:3059- 3067.
16. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. Blood, 2007, p. 109:1857-1861.
17. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia. Costa S, Scott DW, Steidl D, Peacock SJ, Regier DA. Curr Oncol, 2019, p. 26(2):108–113.
18. Incidence of hypogammaglobulinemia in patients receiving Rituximab and the use of intravenous immunoglobulin for recurrent infections. Casulo C, Maragulia J, Zelenetz AD. Clinical Lymphoma, Myeloma & Leukemia, 2013, p. Vol. 13, No. 2, 106-11.
19. Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma. Biggar RJ, Christiansen M, Rostgaard K, Smedby KE, Adami HO, et al. Int J Cancer, 2009, p. 124(11):2616-20.
20. Low circulating B lymphocytes in newly diagnosed follicular and diffuse large B cell lymphoma: differences compared to normal subjects and possible prognostic role. Bruna R, Geuna M, Scalabrini DR, Cignetti A, Santoro N, et al. Blood, 2017, p. 130 (Supplement 1):1482.
21. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC. Ann Transl Med, 2019, p. 7(5):105.
22. ?? T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. Braza MS, Klein B, Fiol G, Rossi JF. Haematologica, 2011, p. 96(3):400-7.
23. Improving immunotherapy against B-cell malignancies using ?? T-cell-specific stimulation and therapeutic monoclonal antibodies. Hoeres T, Pretscher D, Holzmann E, Smetak M, Birkmann J, Triebel J, et al. J Immunother, 2019, p. 42(9):331-344.
24. Role of Fc-Fc?R interactions in the antitumor activity of therapeutic antibodies. Barnhart BC, Quigley M. Immunol Cell Biol, 2017, p. 95(4):340-346.
25. Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, et al. JCO, 2018, Vol. 77.
26. Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival. Tarella C, Gueli A, Delaini F, Rossi A, Barbui AM, Gritti G,et al. PLoS One, 2014, p. 9(9):e106745.